NCT03995355CompletedNot Applicable
Clinical Evaluation of an Investigational Lipid Drop in Non-contact Lens Wearing Patients
Johnson & Johnson Vision Care, Inc.2 sites in 1 country161 target enrollmentStarted: June 26, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 161
- Locations
- 2
- Primary Endpoint
- Change From Baseline Ocular Comfort (30-Day)
Study Overview
Brief Summary
This is a double-masked, randomized, bilateral, 2-Arm parallel group study. Subjects are scheduled for 3 study visits (screening/baseline, 7-Day and 30-Day follow-up visits) over a period of one month.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 69 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Potential subjects must satisfy all the following criteria to be enrolled in the study:
- •Subjects must be at least 18 years of age and no more than 69 years of age (inclusive).
- •Subjects must be non-contact lens wearers.
- •Subjects must achieve visual acuity of 20/30 or better in each eye, either unaided or best corrected.
- •Subjects must possess a functional/usable pair of spectacles and bring them to every visit (only if applicable - to the investigators discretion).
- •Self-reported symptoms of ocular dryness or irritation and/or the use of artificial tears in the last 3 months.
- •Subjects must read, understand, and sign the Statement of Informed Consent.
- •Subjects must appear able and willing to adhere to the instructions set forth in this clinical protocol.
Exclusion Criteria
- •Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- •Currently pregnant or breast-feeding.
- •Any ocular or systemic allergies or disease which may interfere with the clinical trial (at the investigator's discretion).
- •Any systemic disease, autoimmune disease, or use of medication which may interfere with the clinical trial (at the investigator's discretion).
- •Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV), by self-report.
- •Any Grade 3 or greater biomicroscopy findings (this includes, corneal edema, corneal staining, corneal vascularization, conjunctival injection, tarsal abnormalities, bulbar injection) on the FDA scale.
- •Any active ocular abnormalities/conditions that may interfere with the clinical trial (this includes, but not limited to, chalazia, recurrent styles, pterygium, infection, etc.).
- •Any corneal distortion due to previous rigid gas permeable lens wear, surgery or pathology.
- •History of any ocular or corneal surgery (e.g. RK, PRK, LASIK).
- •Participation in any pharmaceutical or medical device related clinical trial within 30 days prior to study enrollment.
- •History of binocular vision abnormality or strabismus.
- •Habitual wearers of soft contact lenses in the past 1 month or rigid gas permeable lens within the past 3 months.
- •Current habitual use of Prescription Medicines to treat dry eye or ocular discomfort, ocular steroids, or any medication (RX or OTC) that would interfere with the clinical study (at the discretion of the investigator).
- •Employees of investigational clinic (investigator, coordinator, and technician, etc.) or family member of an employee of the clinical site by self-report.
- •In addition to the above criteria, patients with any allergy or sensitivity to ingredients that this product may contain (Castor Oil, Polyoxyl 40 Hydrogenated Castor Oil, Sodium Chlorite, Boric Acid, Sodium Borate Decahydrate, Sodium Chloride, Potassium Chloride, Calcium Chloride Dihydrate, Magnesium Chloride Hexahydrate, Polyethylene Glycol 400, Sodium Hyaluronate, Purified Water) should not participate in the study.
Outcomes
Primary Outcomes
Change From Baseline Ocular Comfort (30-Day)
Time Frame: Baseline and 30-Day Follow-up
Subjective overall ocular comfort was assessed at baseline, and at the 30-Day follow-up using a Visual Analogue Scale (VAS) ranging from 0 (extremely uncomfortable) to 100 (extremely comfortable). The change from baseline ocular comfort score was calculated as 30-Day follow-up score minus Baseline score. Change from Baseline VAS Scores range from -100 to 100, where higher change from baseline comfort scores indicates better performance. The average change from baseline comfort score for each Arm was report.
Secondary Outcomes
- Change From Baseline Ocular Comfort (7-Day)(Baseline and 7-Day Follow-up)
- Number of Subject Eyes That Reported Ocular Symptoms(7-Day Follow-up and 30-Day Follow-up)
- Number of Subject Eyes That Experience Grade 2 or Higher Corneal Staining(7-Day Follow-up and 30-Day Follow-up)
- Change From Baseline Ocular Vision (7-Day)(Baseline and 7 Day-Day Follow-up)
- Change From Baseline Ocular Vision (30-Day)(Baseline and 30 Day Follow-up)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 3
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)Mixed HyperlipidemiaNCT00289900Merck Sharp & Dohme LLC2,340
Completed
Phase 2
Safety Study of BMS-770767 in Subjects With HypercholesterolemiaDyslipidemiaNCT01058083Bristol-Myers Squibb81
Completed
Phase 3
Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)Primary HypercholesterolemiaMixed DyslipidemiaNCT00479388Merck Sharp & Dohme LLC1,216
Completed
Phase 2
Safety Study of BMS-823778 in Subjects With HypercholesterolemiaDyslipidemiaNCT01112423Bristol-Myers Squibb60
Completed
Phase 3
MK-0524B Lipid Study (MK-0524B-063)Primary HypercholesterolemiaMixed DyslipidemiaNCT00479882Merck Sharp & Dohme LLC2,414